Increasing evidence has underscored KIFC1's potential as a prognostic biomarker in various cancers, including hepatocellular carcinoma,[20, 22, 25] esophageal squamous cell carcinoma,[24] bladder cancer,[21] and prostate cancer.[47] Consistent with these findings, our study identified KIFC1 as a novel prognostic biomarker in STS. This evidence concerns the gene KIFC1 and telomere syndrome.